Olivier Veran was born in Saint-Martin d’Heres, in the lsere region, where he spent his all of his childhood and attended school. Son of an engineer and an English teacher, his calling for the field of medicine began at an early age. This was strengthened during his night job as an attendant in an elderly home, serving the most fragile, to finance his studies in Grenoble.

Sensitive to the working conditions of caregivers, assistants and interns in the hospitals of Grenoble, he became involved in union life. After completing his thesis on “Epileptic confusion in the elderly”, Olivier Veran became neurologist at the Grenoble-Alpes University Hospital.

As assistant Head of Clinic of the Intensive Care Unit for Vascular Neurology, he was responsible for patients suffering from cerebrovascular accidents. Subsequently, he managed the day clinic of the Neurological department, receiving over 3.000 patients each year.

His political commitment led him to the French National Assembly in 2012, as Member of Parliament for the 1st district of the Isere. Profoundly committed to equal access to healthcare, he devoted the majority of his parliamentary work to health policies and to the fight against poverty, resulting in him becoming General Rapporteur of the Social Affairs Committee.

To uphold his beliefs in the territory that he is so close to, and which is important to him, Olivier Veran was elected Regional Councilor of the Auvergne-Rh6ne-Alpes region in December 2015. Since December 2019 he chairs the group “La Republique En Marche” (the party of the presidential majority) in this assembly.

On February 16th, 2020, Olivier Veran was nominated Minister of Solidarity and Health. Olivier Veran is the father of two children and is passionate about music.

Before being appointed as the Minister of Higher Education, Research and Innovation, Frédérique Vidal had been the President of the University of Nice Sophia-Antipolis (UNS) since 2012.

She holds a master’s degree in biochemistry from the University of Nice Sophia-Antipolis, a post-graduate degree from the Institut Pasteur and a doctorate from the University of Nice Sophia-Antipolis where she became a lecturer in 1995.

Since 2004, Frédérique Vidal has been a professor of biochemistry, molecular and cell biology at the UNS.

In addition, she was Associate Dean of the Department of Life Sciences from 2007 to 2009 and was appointed Research Assessor to the Dean of the Faculty and then Dean of the Department in 2009.

Previously, she was responsible for internships before becoming the Deputy Director of the post-graduate diploma in Pharmacology.

An outside member of the INSERM Regional Scientific Council from 1999 to 2003, Frédérique Vidal has been on the assessment panel for the master’s degree in virology at the UPMC-Paris Diderot-Institut Pasteur since 2004. She was also co-responsible for the European Tempus project in relation to the implementation of the LMD system in the Balkans, from 2006 to 2009.

Frédérique Vidal has been a “Chevalier” of the French Legion of Honour since 2013.

Budi Gunadi Sadikin is the Minister of health of the Republic of Indonesia, a post he has held since Dec 23 2020. His assignments including leading the COVID-19 vaccination programme and improve health services in the nation. Mr. Sadikin has a distinguished career in the financial industry. He holds a degree in nuclear physics from the Bandung Institute of Technology and completed his business and executive education in Singapore, USA and France.

Jean-Eric Paquet became Director-General of DG Research and Innovation on 1^st April 2018; his involvement in EU research policy dates back from 2002, as Deputy Head of Cabinet of Philippe Busquin, then Commissioner in charge of Research and Development. He also worked in DG Transport, where he led the development of the Trans-European Transport Network Policy. He was also EU Ambassador in the Islamic Republic of Mauritania from 2004 to 2007. Between 2015 and 2018, he was the Deputy Secretary-General of the European Commission in charge of Better Regulation and Policy Coordination. In all his endeavours, he puts co-creation and systemic change at the heart of the decision-making process, and strongly believes that citizens should be more involved in shaping public policy agendas.

Dr Tedros Adhanom Ghebreyesus was elected WHO Director-General for a five-year term by WHO Member States at the Seventieth World Health Assembly in May 2017. In doing so, he was the first WHO Director-General elected from among multiple candidates by the World Health Assembly, and was the first person from the WHO African Region to head the world’s leading public health agency. Born in the Eritrean city of Asmara, Dr Tedros graduated from the University of Asmara with a Bachelor of Biology, before earning a Master of Science (MSc) in Immunology of Infectious Diseases from the University of London, a Doctorate of Philosophy (PhD) in Community Health from the University of Nottingham and an Honorary Fellowship from the London School of Hygiene and Tropical Medicine. Following his studies, Dr Tedros returned to Ethiopia to support the delivery of health services, first working as a field-level malariologist, before heading a regional health service and later serving in Ethiopia’s federal government for over a decade as Minister of Health and Minister of Foreign Affairs.
As Minister of Health from 2005 to 2012, he led a comprehensive reform of the country’s health system, built on the foundation of universal health coverage and provision of services to all people, even in the most remote areas.
Under his leadership, Ethiopia expanded its health infrastructure, developed innovative health financing mechanisms, and expanded its health workforce. A major component of reforms he drove was the creation of a primary health care extension programme that deployed 40 000 female health workers throughout the country. A significant result was an approximate 60% reduction in child and maternal mortality compared to 2000 levels.
As Minister of Foreign Affairs from 2012 to 2016, he elevated health as a political issue nationally, regionally and globally. In this role, he led efforts to negotiate the Addis Ababa Action Agenda, in which 193 countries committed to the financing necessary to achieve the Sustainable Development Goals.

Anthony S. Fauci, M.D. is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio focused on infectious and immune-mediated diseases. As the long-time chief of the NIAID Laboratory of Immunoregulation, Dr. Fauci has made many seminal contributions in basic and clinical research and is one of the world’s most-cited biomedical scientists. He was one of the principal architects of the President’s Emergency Plan for AIDS Relief (PEPFAR), a program that has saved millions of lives throughout the developing world.

Prof. Philippe Sansonetti is MD, he trained in infectious diseases in Paris hospitals and in bacterial genetics at Institut Pasteur, Paris, then at the Walter Reed Army Institute of Research as a post-doctoral scientist. He is currently Emeritus Professor at Institut Pasteur and at the Collège de France, and Chief Scientist at Institut Pasteur Shanghai.
He pioneered the field of Cellular Microbiology by deciphering the molecular and cellular mechanisms of Shigella pathogenesis. He more recently applied similar approaches to decipher the symbiotic mechanisms established between the host and his gut microbiota. His work on Shigella vaccine development got him close to global health issues in low-income countries, particularly in Africa. Philippe Sansonetti is a member of the French “Académie des sciences”, and a foreign member of the US National Academy of Sciences and of the Royal Society.

After studying at the Ecole Normale Supérieure, where she specialized in economics and social issues, Marisol Touraine studied at the Institute of Political Studies in Paris as well as at the prestigious Harvard University in the United States. She served as an Adviser to the Prime Minister from 1988 to 1991 in charge of geostrategic issues, and she became a member of the Council of State in 1991. She then held the positions of Member of Parliament and General Councilor of Indre et Loire for several years before being appointed Minister of Social Affairs, Health and Women’s Rights (2012-2017). She distinguished herself in this position in particular by her measures in favor of the authorization and financial coverage of innovative HIV prevention methods as well as by her fight in favor of neutral cigarette packs, which earned her the WHO award in 2016. She has been Chair of the Unitaid Board since June 2019.

A pioneer in global public health for more than 35 years, Dr Seth Berkley has been a champion of equitable access to vaccines and of innovation, and a driving force to improve the way the world prevents and responds to infectious disease. A medical doctor and infectious disease epidemiologist, Dr Berkley joined Gavi, the Vaccine Alliance as its CEO in August 2011. During his tenure, Gavi has increased coverage of routine immunisation in lower-income countries: even before the COVID-19 pandemic, Gavi was helping protect nearly half the world’s children, vaccinating more than 820 million people in its first 20 years, reducing vaccine-preventable child deaths by 70% and preventing more than 14 million deaths. In 2020, Dr Berkley co-created COVAX, the only multilateral global solution aimed at ending the acute phase of the pandemic by providing equitable access to COVID-19 vaccines for people in all countries, regardless of their ability to pay. Prior to Gavi, in 1996, Dr Berkley founded the International AIDS Vaccine Initiative (IAVI), where he served as President and CEO for 15 years. Previously, Dr Berkley worked for The Rockefeller Foundation, the US Centers for Disease Control and Prevention; the Massachusetts Department of Public Health; and the Carter Center, where he was assigned as an epidemiologist at the Ministry of Health in Uganda. Dr Berkley sits on a number of international steering committees and corporate and not-for-profit boards; has held academic appointments at Brown, Columbia and New York Universities; and is currently an Adjunct Professor at the University of Geneva. Dr Berkley received his undergraduate and medical degrees from Brown University and trained in internal medicine at Harvard University. In 2013, he was awarded an Honorary Doctorate by Nelson Mandela University in Port Elizabeth, South Africa. In 2021, Dr Berkley received an Honorary Doctor of Science degree from Makerere University School of Public Health in Uganda.

Trevor Mundel leads the foundation’s efforts to develop high-impact interventions against the leading causes of death and disability in developing countries. He manages the foundation’s disease-specific R&D investments in HIV, tuberculosis, malaria, pneumonia, enteric and diarrheal diseases and neglected tropical diseases. He also manages cross-cutting product development programs, including Discovery & Translational Sciences, Innovative Technology Solutions, Integrated Development, and Vaccine Development & Surveillance. This work relies on close collaboration with an international network of grantees and partners.

Trevor spearheaded the creation of the Bill & Melinda Gates Medical Research Institute, and leads the foundation’s efforts to support the development of diagnostics, therapeutics, and vaccines for the global response to COVID-19.

Prior to joining the foundation in 2011, Trevor was global head of development with Novartis and previously was involved in clinical research at Pfizer and Parke-Davis.

Born and raised in South Africa, Trevor earned his bachelor’s and medical degrees from the University of the Witwatersrand in Johannesburg. He also studied mathematics, logic, and philosophy as a Rhodes Scholar at Oxford University, and he earned a Ph.D. in mathematics at the University of Chicago.

Dr Tereza Kasaeva, MD, PhD is the Director of the World Health Organization’s (WHO) Global Tuberculosis Programme. Since 2018, she has been leading WHO’s work on norms, policies and standards on TB prevention and care; technical support to countries, including through the three-level WHO TB technical expert network; monitoring the global TB epidemic; promoting TB research & innovations and strengthening political and multisectoral engagement, accountability and advocacy to End TB. Dr Kasaeva has more than 28 years of experience in public health and in leading innovative efforts for socially significant diseases, including TB, with over a decade with the Ministry of Health of the Russian Federation.

Stéphanie Seydoux has been appointed French Ambassador for Global health in 2018, representing France in various international organizations (Global Fund, Unitaid…). She was involved in the 6^th Global Fund replenishment conference in Lyon, in October 2019 and is currently active in the French multilateral response to the Covid crisis (in particular through ACT-A), which was developed alongside strengthening major health and development priorities such as health system strengthening, gender equality, the fight against pandemics for instance.

After starting her career at the Ministry of Foreign Affairs, Stéphanie Seydoux joined the General Inspectorate of Social Affairs (IGAS) in 2004. From 2007 to 2010, she was Head of Equality Promotion at the French Independent Equality Commission. From 2010 to 2013, she was Deputy Ambassador at the French Embassy in Kenya. She was head of the French Women’s rights department from 2014 to 2017.

Stéphanie Seydoux holds a master’s degree in literature from the University of Oxford, a graduate of the Paris Institute of Political Studies (Sciences Po) and is a former student of the National School of Administration (ENA) – promotion “Léopold Sédar Senghor”

Dr. Barbara Kerstiëns, MD, MPH is the Head of Unit in the unit responsible for ‘Combatting Diseases’ in the PEOPLE Directorate of the Directorate-General for Research and Innovation at the European Commission. She has a long experience in international public health, working for Médecins Sans Frontières, Johns Hopkins Bloomberg School of Public health and DG Development and Cooperation of the European Commission prior to joining DG Research and Innovation in 2012 where she has consistently worked in medical research and funding. Barbara Kerstiëns received her M.D. from the Katholieke Universiteit Leuven, a Postgraduate Certificate in Tropical Medicine from the Institute of Tropical Medicine in Antwerp and a Master of Public health from Johns Hopkins Bloomberg School of Public Health.

Dr. Maria Rosario Singh-Vergeire is the current Undersecretary for the Public Health Services Team and the official spokesperson of the Philippine Department of Health. She was previously the OIC-Undersecretary for Health Regulation Team and Assistant Secretary in charge of the Public Health Services Team. She also acted as OIC- Deputy Director-General Field Regulatory Operation – Food and Drug Administration, Office Director of the Health Facilities and Services Regulatory Bureau, and Chief of the Health Research Division of the Health Policy Development and Planning Bureau. Undersecretary Vergeire has committed decades to public service, having worked in Marikina City’s health office before joining the Department of Health in 2007. Aside from public service, she is also committed to nurturing our soon-to-be public health leaders serving as faculty at the Development Academy of the Philippines and part-time faculty in Ateneo School of Government. She obtained her undergraduate degree in Zoology from the University of Santo Tomas, her MD from De La Salle University College of Medicine, and her MPH from the University of the Philippines, Manila.

Carol is a renowned international TB/HIV activist, a passionate community representative who uses her personal experience with TB/HIV. She is Executive Director of CITAMplus, an NGO based in Zambia which works closely with NTP and a member of MoH TB TWG. She is board member representing affected communities on the boards of Stop TB Partnership and TBPeople and in the past Unitaid, Global Fund and The Union. At national levels she is FPP of the Parliamentary TB Caucus, national Stop TB Partnership and chairperson of CSOs TB network. Also past president of Africa Coalition on TB and a diagnostic champion.

Patrick is a Global Health specialist with experience working on diverse health topics including TB for management consulting and NGOs in Africa. He acts in a chair capacity for the Global Tuberculosis Community Advisory Board and is a member of the COVID-19 task force for Cote d’Ivoire. Patrick received a PharmD from Cheikh Anta Diop University (Dakar), a Master in Health Economics from the African Center for Advanced Management Studies and a Master in Development Practice from Sciences Po Paris.

Ms. Ashna Ashesh is a lawyer, public health professional and MDR TB Survivor associated with Survivors Against TB (SATB), a community group that works with TB survivors and diverse stakeholders to advocate on creating patient and community focussed paradigms of care in TB in India. Ashna’s work focuses on TB and mental health, gender and TB, and diversity, equity and inclusivity in patient support and care.  She is a widely published writer and a strong voice in TB advocacy.

After graduating from UC Berkeley and Albert Einstein College of Medicine, he trained at Brigham & Women’s Hospital and Harvard Medical School. There, he practiced Rheumatology and established his lab, which focuses on immunity to tuberculosis. After 23 years, he joined the University of Massachusetts Medical School, where he is currently Professor of Microbiology and Physiological Systems. Dr. Behar’s lab has made important contributions to our understanding of T cell immunity to tuberculosis. The lab’s ultimate goal is to determine the immunological basis for protective immunity so it can be leveraged in vaccine design and the development of novel vaccine strategies.

Marco Cavaleri is Head of Office, Biological Health Threats and vaccines strategy. He is the Chair of EMA COVID Task force and responsible for EMA activities for emergent pathogens, vaccines and AMR.

Marco Cavaleri is a Pharmacologist who spent several years in industry in R&D mainly in the area of anti-infectives covering different positions in preclinical and clinical development.

In 2005 he joined the EMEA as Scientific Administrator in the Scientific Advice and Orphan Drugs Sector, specifically being in charge of anti-infectives and vaccines scientific advice procedures.

In 2009 he was appointed as Head of Section for Anti-infectives and vaccines in the Safety & Efficacy Sector, Human Medicines Development and Evaluation Unit.

Stewart Cole is an internationally renowned scientist and Professor of Microbial Pathogenesis. Since January 2nd, 2018, he is President of the Institut Pasteur.
From 2007 to 2017, he has served as Professor and Director of the Global Health Institute at the Ecole polytechnique fédérale de Lausanne, the Swiss Federal Institute of Technology (EPFL) – a world-leading education and research center.

For 24 years Cole worked as a researcher and also held various research management positions at the Institut Pasteur. He was Director of Strategic Technologies and then Executive Scientific Director, contributing to several patent applications relating to HIV/AIDS, cervical cancer and multidrug-resistant tuberculosis. He participated in the Scientific Advisory Boards of the Institut Pasteur in Iran, the Institut Pasteur in Montevideo and the Institut Pasteur in Lille. Professor Cole was also acting President of the Institut Pasteur in Paris in 2005.
He has been the recipient of many national and international prizes and distinctions. In 2009, he was awarded the World Health Organization’s prestigious Stop-TB Partnership Kochon Prize for his leadership and groundbreaking accomplishments in genetic research on M. tuberculosis and his contribution to novel therapeutic strategies for tackling TB.
During his career, he has been involved in the work of several foundations and scientific committees, and was notably Chair of the board of the Innovative Medicine for Tuberculosis Foundation and President of the commission médicale for the Fondation Raoul Follereau.
Stewart Cole has also published more than 350 scientific papers on infectious diseases, most notably tuberculosis and leprosy.
Professor Cole was awarded with the title of Chevalier of the Legion of Honor in 2004 and was appointed as Knight Commander of the Order of St. Michael and St. George for service to science, on January 1st, 2022.

Dr Darragh Duffy leads the Translational Immunology Lab at the Institut Pasteur in Paris, where he is also co-coordinator of the LabEx Milieu Interieur Consortium. The overall goal of his research is to better understand the fundamental mechanisms behind inter-individual differences in immune responses, and apply these discoveries to relevant clinical questions. To do this his team uses cellular mechanistic models, population immunology cohorts, and experimental clinical studies in infection and autoimmunity. He has specific interest in cytokine biology, with a focus on the role of type I interferons in response to viral infection and as a common trigger in autoimmune disease.

Bernard Fritzell, MD has been an independent consultant in vaccinology and vaccine development at BFL conseils SAS since 2012 after 30 years in the vaccine industry. Dr Fritzell was Vice President, International Scientific & Clinical Affairs for Wyeth/Pfizer Vaccines (1999-2011). Dr Fritzell has gained experience in vaccine clinical trial programmes set-up across Africa, Asia, Europe and the USA and directed all phases of vaccine development.They have included research into paediatric and adult vaccines and new adjuvants. From 1996 to 2010, Dr Fritzell has been Chairman of the clinical working group of the European Vaccines Manufacturers (EVM).

Baoxue Ge is a professor Tongji University. Director of Shanghai Key Laboratory of Tuberculosis (lung). He has long been engaged in the functional mechanism and clinical translational application of innate immune molecules. He has published more than 90 research papers in Nature, Science, Nature Immunology, Cell Research, Cell Host & microbe, Nature Microbiology, Nature Communications and other academic journals. 23 invention patents were applied for and 6 were authorized. He has been invited to serve as Deputy Editor-in-Chief of Chinese Journal of Cell Biology. Editorial board of Cellular & Molecular Immunology, Pathogens, Tuberculosis, Microbes & Infection.

Dr Birgitte Giersing is a team lead in the Product and Delivery Research Unit, in the Immunization, Vaccines and Biologicals (IVB) department, WHO. She leads IVB’s work on new TB vaccines, and the TB Vaccine Accelerator secretariat within the Science Division. As the secretariat for IVB’s Product Development for Vaccines Advisory Committee (PDVAC), her role includes establishing new tools and mechanisms to identify vaccine R&D priorities, and to effectively partner with country, regional and global immunization stakeholders to accelerate regulatory approval and uptake in low- and middle-income countries. Birgitte has been at WHO for almost 10 years, and previously held vaccine product development roles in industry and the non-profit sector.

Dr. Rajesh S. Gokhale is the Secretary at Department of Biotechnology in the Ministry of Science & Technology, Government of India. He is presently on deputation from Indian Institute of Science Education & Research (IISER) Pune. Dr. Gokhale is trained as a chemical biologist and his significant scientific contributions are in elucidating complex interplay between metabolic reprogramming and inflammation in the context of infectious disease Tuberculosis and autoimmune skin disorder Vitiligo.

Professor Mark Hatherill is Director and leader of the clinical research team of the South African Tuberculosis Vaccine Initiative (SATVI), a University of Cape Town research group focused on understanding risk for and protection against TB, to develop better vaccines and preventive therapies to impact the global epidemic.
A University of Cape Town medical graduate, he trained as a pediatrician and critical care sub-specialist. He has led several clinical trials of novel TB vaccine candidates in infant, adolescent and adult populations. He is Co-PI of the Regional Prospective Observational Research in Tuberculosis (RePORT) South Africa consortium. His work focuses on the design and implementation of clinical trials of novel TB vaccines and studies of biomarkers of TB risk.

Honourable Dr Christopher Kalila trained as a Medical Doctor and served mostly as a General Practitioner and a Family Practitioner for over seventeen (17) years before entering the world of politics through being nominated to Parliament and appointed Deputy Minister of Youth Sports in 2008. He served in the same capacity in the Ministry of Works and Supply in 2009 before being reassigned as Deputy Minister of Health in 2010 until September 2011 when Zambia again went for general elections. He contested the elections and won the Lukulu East Parliamentary seat which he held for 5 years and also served as Chairman of the Parliamentary of Education. In 2016 he contested the same seat and won. During this period he served as Chairman of the Parliamentary Committee on Health, Community Development and Social Services, and Chairman of the Zambian TB Caucus. In the recently held national elections (2021), Hon Kalila managed to retain his seat and continues to advance the interest of the TB Caucus.

Bertrand is a Public health expert with special focus on health and Community Systems Strengthening, gender and human rights and a dozen years of experience in planning, management, monitoring and evaluation of health projects. Over the last five years he has carried out more than 15 technical assistance missions in West and Central Africa to scale up TB preventive treatment, capacity building of health care providers, sustained community involvement including TB survivors, reduction of gender and human rights barriers as well as ethical considerations. He also supporting National TB Programs in the region to strengthen community-based active TB case finding and human rights approaches to close the notification gap. In 2018, he joined the World Health Organization TB Civil Society Task Force to help translate WHO’s TB policies, including the End TB Strategy, into practice by integrating the views of TB affected communities and their networks at global, regional and national levels. Bertrand has a Master in Public Health (Health Promotion) from the Faculty of Medicine, University of Lorraine, Nancy School of Public Health in France.

Maureen Kamene Kimenye Mariita is a Kenyan physician and medical administrator, who currently serves as a Technical Assistant in the Directorate of Public Health at Ministry of Health Kenya, where she works on the nation’s COVID response. She previously served as the Head of the National Tuberculosis, Leprosy & Lung Disease Control Programme, in the Kenyan Ministry of Health. She is a leading authority in the treatment and control of TB in Sub-Saharan Africa and has spent about 15 years working in the public policy, primarily with TB, HIV, and Malaria. Maureen received her medical degree from Moi University, her Master’s in Public Health from Jomo Kenyatta University and her diploma in TB control and Epidemiology from the Research Institute of Tuberculosis (RIT) in Japan. She spent a year in a fellowship program, studying MDR TB and HIV/AIDS in Lesotho.

Dr. Leonid Lecca is a Peruvian physician and researcher serving as the Executive Director of international NGO Socios En Salud (SES, Spanish for “Partners In Health”) and as a Lecturer at the Department of Global Health and Social Medicine at Harvard Medical School. He is also Vice-Chair of the Regional Green Light Committee for DR-TB for Latin America and the Caribbean (LAC) and is a member of the America TB Coalition. During the last two years, his organization launched the formation of TB Social Observatories in 8 LAC countries, as spaces of social vigilance, political incidence and experiences exchanges for TB civil society in the Americas.

My group investigates innate and adaptive immune response to TB and HIV infection. We are particularly interested in the responses occurring within tissue, which are studied using locally available excess material from surgical procedures. This allows us to investigate the host-pathogen interaction at the site of disease and to try and understand the relationship between the immune responses occurring in infected human tissue, and those that are detectable with in the blood. We make use of advanced flow cytometry and mass cytometry, single cell RNA sequencing, immunofluorescent histology and 3D tissue culture to investigate the phenotype and function of tissue resident immune populations. The aim, is to uncover new biology that will aid the development of novel therapeutic interventions and improve the health of individuals afflicted with these deadly infections.

Rhea Lobo is an international award-winning filmmaker with a background in health journalism and is also an extra-pulmonary TB survivor. She is a strong TB advocate and co-founder of Bolo Didi (Translation: Say Sister), an informal network of women TB survivors in India that help people affected by TB navigate health systems, promote treatment adherence and counselling. She has extensive experience in working for both Communicable and Non-Communicable Diseases in organizations such as Dalberg Media, The Union and TBpeople. She is of Indian origin and currently resides in Copenhagen, Denmark. Rhea has made a number of films on health and women empowerment, with a special interest in TB. Her film on Human Rights and TB, Rights and Wrongs… A Tribute to Dean Lewis, received critical acclaim from Dr Tedros Adhanom, Director General of the World Health Organization. Rhea is also a member of the Stop TB Working Group on New Vaccines and is part of the taskforce that is developing Stop TB Partnership’s Global Plan to End TB by 2030.

Laleh Majlessi, PhD, Associate Professor at Institut Pasteur, France, is interested in the host-mycobacteria interaction and notably the immunogenicity of the substrates of mycobacterial type VII secretion systems, which has applications in the development of new TB vaccine candidates. She was awarded the Jean-Marie Dubert Prize for her Ph.D thesis in cellular immunology and the Georges, Jacques and Elias Canetti Prize for her research on anti-mycobacterial immunity. She is member of the Collaboration for TB Vaccine Development (CTVD) and is presently the deputy scientific director of Pasteur-Theravectys Joint Lab at Institut Pasteur, which develops subunit vaccinal vectors against infectious diseases.

Dr Shekhar C. Mande is an Indian Structural and Computational Biologist. He did his M.Sc. in Physics from University of Nagpur and earned Ph.D degree in Molecular Biophysics from Indian Institute of Science. Following his PhD in 1991, he joined Prof. Wim G. J. Hol as Post-Doctoral Fellow at Rijksuniversiteit Groningen in the Netherlands and in 1992 he joined University of Washington, Seattle as Senior fellow. He returned to India in 1995 to serve as Scientist in Institute of Microbial Technology. In 2001 he joined the Centre for DNA Fingerprinting and Diagnostics as senior Staff Scientist. Dr Mande led the National Centre for Cell Science as its Director from 2011 to 2018. Since 2018 he is serving as the Director General of Council of Scientific and Industrial Research (CSIR) and Secretary, Department of Scientific and Industrial Research (DSIR), Govt of India. He has been serving many advisory committees including task forces of many S&T related departments of Govt of India. Dr Mande is a fellow of several professional bodies and has been conferred many awards and honors which includes Shanti Swarup Bhatnagar Prize for Science and Technology, the highest science award in India.

Dr. Mayer-Barber received her diploma from the University of Würzburg, Germany, in 2002 and doctoral degree in 2006 from the University of Würzburg for work carried out at the Trudeau Institute. She joined NIAID in 2007 as a postdoc in the Laboratory of Parasitic Diseases. Dr. Mayer-Barber was awarded the Earl Stadtman Tenure-Track Investigator position in the NIAID Laboratory of Clinical Immunology and Microbiology in 2015. Her work is focused on innate immune cells, inflammatory cytokines and lipid mediators as targets for potential host-directed therapies and improved vaccine adjuvant design in murine and nonhuman primate models of TB disease.

Dr. Mortensen received his doctorate in immunology and vaccinology at University of Copenhagen and is Head of TB Vaccine Research at Statens Serum Institut in Copenhagen, Denmark. His responsibilities cover development activities from early discovery and vaccine design to testing and transitioning into clinical trials. His group is studying protective immunological mechanisms of vaccine mediated immunity with a specific focus on Th1/Th17 cells and utilize the knowledge gathered in clinical trails and animal experiments to generate better next-generation TB vaccines.

Doreen Pamba is a Social Scientist employed at the National Institute for Medical Research-Mbeya Medical Research Centre (NIMR-MMRC) in Tanzania. She has a degree in Medical Sociology, Masters of Philosophy in International Health and is currently a PhD student at University of Munich, Germany. Ms. Pamba has coordinated community engagement activities since 2010 in TB drug and vaccine trials as well as HIV vaccine trials. She also has experience in implementing qualitative research nested in these clinical trials and in mixed methods TB and HIV operational research.

Puck Pelzer is an Epidemiologist at KNCV tuberculosis foundation. As of early 2018 she provides technical support at KNCV on several international projects and is the lead on TB vaccine projects. In addition Puck is in the final stages of obtaining an PhD. Puck started her career in global health at the Department of Health Sciences at VU University working on the effects of vaccines in LMIC. Puck has a professional membership in the board of the Dutch Society for Tropical Medicine & International Health and as Early Career Researcher in the Stop TB partnership’s working group on New TB vaccines

Antoine Petit obtained a Master Degree in Mathematics from University Paris Sud (1981) and then “Agrégation de Mathématiques” (1982). He received his PhD in Computer Science from Paris Diderot University (1985).

He joined University of Orléans as « Assistant » in 1984, then he worked in University Paris Sud (now, part of University Paris-Saclay) as « Maître de Conférences » in 1989.

In 1994, he joined ENS Paris – Saclay (formerly ENS de Cachan) as full Professor and became head of the Computer science department from 1995 to 2001.

In 2002, he was appointed as Deputy Director of the French ministry of research, in charge of mathematics, information and communication science. In 2004, he joined CNRS as Director of the Information & Communication Sciences and Technologies Department and then as Regional Director for South West of France.

In 2006, he was recruited by INRIA where he has been successively: center of Paris Research Director – Rocquencourt, deputy CEO in 2010 and then President and CEO in 2014.

Since January 2018, he is President and CEO of CNRS.

Antoine Petit is Doctor Honoris Causa from the University of Chile, « Chevalier de la Légion d’Honneur » and « Officier de l’Ordre National du Mérite ».

Dr. Louis J. Picker is the Associate Director of the Vaccine and Gene Therapy Institute, a Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center, and a Professor of Pathology at the Oregon Health & Science University. Dr. Picker’s lab is focused on the elucidation of memory T cell physiology in non-human primates, including mechanisms of T cell-mediated protection against persistent pathogens, immunopathogenesis of AIDS-causing lentiviruses and M. tuberculosis, development interventions for HIV cure, and development of effective HIV/AIDS and tuberculosis vaccines.

Matthew is Assistant Professor in Health Economics in the TB Modelling Group at the London School of Hygiene and Tropical Medicine. Matthew works at the interface of health economics and infectious disease modelling, working on projects assessing the impact and cost-effectiveness of a range of infectious diseases in various settings worldwide. Alongside colleagues in the TB modelling group, Matthew‘s current focus is estimating health and economic benefits of new TB vaccines and delivery mechanisms.

Lele is Clinical Associate Professor at the Institute of Global Health and the MRC Clinical Trials Unit at University College London (UCL). She is also an honorary Associate Professor at her alma mater, University of Cape Town in South Africa.

She is an ID Clinician Scientist with 20 years of experience. Her research areas span the epidemiology of poverty-related diseases, randomized assessments of public health technology, digital health innovation and implementation science. Her team conducts clinical trials of TB prevention across multimorbidities, people at risk, and world regions. She holds a Wellcome Trust Investigator and EDCTP awards to conduct multi-country research on TB, NCD and TB prevention.

Lele sits on a number of international working groups including TB-LEAP, Collaboration for TB Vaccine Discovery (CTVD), the Cross-Network TB Vaccine Working Group (TB Vaccine WG), Maternal and Child Working Group of the Union, the LTBI Task Force of the StopTB New Diagnostic Working Group, and is a member of the Lancet Digital Health International Advisory Board and UCL-TB Leadership.

Mukta Sharma is the WHO Regional Advisor for TB/HEP/HIV/STIs at the Southeast Asia Regional Office. Mukta is leads the WHO South East Asia Region’s response to HIV/STIs/TB and Hepatitis in eleven countries. She has over fifteen years with UNAIDS, UNICEF, and the World Health Organization, with a strong understanding of UN agencies and donors, and is skilled in working in partnership with Ministries of Health, law enforcement, community partners, and sub-national stakeholders. She is a subject expert in communicable diseases with master’s level trainings in Epidemiology from the London School of Hygiene and Tropical Medicine and a PhD from the London School of Economics.

Rajinder Suri is CEO-DCVMN responsible for leadership, governance, strategic orientation and operational excellence. Rajinder is member of COVAX Manufacturing & Supply Task Force Leadership Team, MI4A (Market Information for Access to Vaccines) Advisory Group to WHO on Malaria, Global TB Vaccines R&D Roadmap by EDCTP, Expert Group on Seasonal Influenza Vaccine and Market Design and Demand Intelligence pillar of the Partnerships for African Vaccine Manufacturing (PAVM). With 43 years of experience and deep insights of the industry including Pharmaceuticals and Biological products in India and International markets, has invested over 24 years at the top management level including four years on the Board of Directors of the Indian subsidiary of Sanofi Pasteur. Rajinder has been Member-Gavi-Policy & Planning Committee (PPC) as well as Vice-President, DCVMN Executive Committee (2014-16).